Nureca Q2 FY27 results: Revenue up 55% to ₹58.53 cr

Strong top-line quarter for a micro-cap healthcare player

Nureca Ltd reported a sharp jump in quarterly revenue for Q2 FY27, driven by demand in its home healthcare and wellness products business. Consolidated revenue from operations rose to ₹58.53 crore for the quarter ended 30 September 2026, a 55% year-on-year increase. The company described the quarter as a new high in net sales, with operating metrics also improving versus the year-ago period. At the same time, profitability improved at the net level but trailed the pace of revenue growth as costs climbed. Nureca has also been navigating a transition towards domestic production, which has been part of the broader operational context.

Revenue jumps 55% YoY and 45% QoQ

On the revenue line, Nureca’s consolidated revenue from operations came in at ₹58.53 crore (₹58.526 crore based on the ₹585.26 million figure cited). This compares with ₹37.74 crore in Q2 FY26, implying a 55.1% year-on-year increase. Sequentially, the company’s revenue also improved from ₹40.34 crore in the preceding quarter (Q1 FY27), reflecting a 45% quarter-on-quarter rise as cited in multiple summaries.

The company also disclosed standalone revenue from operations of ₹58.60 crore for Q2 FY27 (₹585.99 million), which was compared with ₹37.84 crore in the year-ago quarter (₹378.41 million). Across disclosures, the broad takeaway remained consistent: Nureca delivered its strongest quarterly revenue in several years, with some reports describing it as the highest quarterly figure in 20 quarters.

Profit rises, but growth trails revenue

Profitability rose in Q2 FY27, with reported consolidated profit after tax (PAT) of about ₹4.05 crore to ₹4.1 crore for the quarter. One summary pegged net profit at ₹4.1 crore, while another highlighted PAT of ₹4.05 crore and an 11.7% YoY increase. Earnings per share (EPS) was reported at ₹4.25, up from ₹3.63 a year earlier.

There were also disclosures that separated “net profit after tax from continuing operations,” stated at ₹3.07 crore for Q2 FY27, alongside a comparison to ₹4.05 crore in Q1 FY27 and ₹3.63 crore in Q2 FY26. Investors tracking the print typically focus on the company’s headline PAT figure and its accompanying notes, especially when multiple profit measures are referenced across summaries.

Operating profit improves, margins soften

Operating performance improved in absolute terms. Operating profit was reported at ₹5.23 crore in Q2 FY27, up 60% from ₹3.27 crore a year ago. The company also reported PBDIT of ₹5.24 crore for the quarter, signalling better operating scale.

However, margins moved in the opposite direction. Operating margin for the quarter was reported at 9.2%, down from 11.5% in the year-ago quarter and 10.4% in Q1 FY27. Cost pressure was visible in the expense line, with one report citing total expenses rising to ₹54.36 crore from ₹35.46 crore a year earlier. Another cost driver highlighted was the purchase of stock-in-trade, which rose to ₹52.17 crore.

Other income and total income snapshot

Beyond core operations, other income was reported at ₹1.35 crore for Q2 FY27 (₹13.53 million), taking total consolidated income to ₹59.88 crore (₹598.79 million). In the YoY comparison table, other income was shown at ₹1.35 crore versus ₹2.32 crore in Q2 FY26, a 41.6% decline.

Profit before tax (PBT) was reported at ₹5.52 crore for Q2 FY27, up 20% from ₹4.60 crore in the year-ago quarter. A separate disclosure stated consolidated profit before tax at ₹5.52 crore (₹55.16 million), matching the same level when expressed in crore.

Half-year performance and ROCE improvement

For H1 FY27, revenue was reported at ₹98.87 crore, up 37.5% year-on-year in one summary (and described as up 37% in another). H1 profit after tax was reported at ₹7.12 crore, up 60.4% year-on-year.

Return on capital employed (ROCE) for the half-year was reported at 5.21%, described as the highest recorded in recent periods. While the ROCE level remains modest, the direction of change was presented as an indicator of improved capital utilisation alongside higher sales.

Promoter holding rises; technical rating upgraded

Promoter confidence was flagged as improving during the period. Promoters increased their stake by 2.59% over the previous quarter to 70.68% of the company.

Separately, Nureca’s investment rating was upgraded from Sell to Hold in one update, citing improved technical indicators and positive quarterly financial results. The coverage positioned Nureca as a micro-cap participant in the healthcare services segment, with quarterly execution supporting a more neutral stance.

Board approval, auditor review, and the earnings date

Nureca said its Board of Directors would meet on 21 October 2026 to consider and approve unaudited financial results for the quarter and half-year ended 30 September 2026. Subsequent updates indicated that the results were reviewed by the Audit Committee and approved by the Board on 21 October 2026.

The statutory auditor, Singhi & Co., Chartered Accountants, conducted a limited review of the standalone and consolidated statements. In addition, the company’s “upcoming earnings date” was also stated as 21 October 2026 in an earnings calendar reference.

Key numbers at a glance

Market impact: what the quarter signals

The Q2 FY27 result establishes that Nureca is currently delivering growth primarily through a stronger top line, with revenue expanding faster than profit. The margin compression and higher costs, including a sharp rise in stock-in-trade purchases and overall expenses, show why profit growth did not match revenue growth despite higher operating profit.

For investors, the quarter also provides tangible markers to track: whether operating margin stabilises after the domestic production transition, whether other income remains subdued versus last year, and whether the company can sustain the higher revenue base seen in Q2. Corporate signals such as increased promoter stake and a rating upgrade to Hold add context, but the operational metrics and cost trajectory remain central to the narrative.

Conclusion

Nureca’s Q2 FY27 performance combined a 55% year-on-year jump in revenue to ₹58.53 crore with net profit reported around ₹4.05 crore to ₹4.1 crore, alongside improved operating profit but softer margins. The company’s board approval on 21 October 2026 formalised the unaudited results, with a limited review conducted by its statutory auditor. The next set of updates for investors will be in subsequent quarterly disclosures, particularly on margins, cost mix, and progress on the shift toward domestic production.